News

Seletalisib Seen to Aid Saliva Production, Lower Inflammation in Mouse Study

The PI3K-delta inhibitor known as seletalisib, an investigative treatment for primary Sjögren’s syndrome, improved the production of saliva, lowered the levels of autoantibodies and inflammatory mediators, and decreased immune B- and T-cell infiltration in salivary glands in a mouse model, study researchers report. The study, “Phosphatidylinositol 3-kinase delta…

Rising Healthcare Costs Strain EU Budgets Even as New Therapies Flourish

Cash-strapped governments across the 28-member European Union are struggling to control runaway healthcare expenditures — at exactly the same time as the promise of new but expensive therapies to treat rare diseases has never been greater. That’s the paradox faced by pharmaceutical companies as well as patient advocacy groups in…

Vaginal Dryness and Pain Can Affect Sexual Intimacy in Primary Sjögren’s Patients, Study Finds

Difficulties with engaging in sex — including arousal, lubrication, orgasm, and satisfaction — are significant in women with primary Sjögren’s syndrome compared to healthy women, and sexual function decreases as disease duration increases, a study reports. The findings, “Primary Sjögren’s Syndrome Adversely Affects the Female Sexual Function Assessed by…

Leflunomide-Hydroxychloroquine Combo Shows Potential for Sjögren’s Patients in Pilot Trial

A combination of leflunomide and hydroxychloroquine significantly reduced disease activity, increased salivary flow, and improved patient-perceived health in patients with primary Sjögren’s syndrome, a pilot trial showed. Findings of the trial were revealed at the recent American College of Rheumatology 2018 Meeting, in Chicago. Timothy Radstake, MD, PhD, from the …

MeiraGTx Acquires Rights to AAV-AQP1 Gene Therapy for Sjögren’s Syndrome

MeiraGTx recently acquired global rights over an investigational gene therapy called AAV-AQP1 being developed to treat the excessive dry mouth and eyes experienced by patients with Sjögren’s syndrome. The announcement comes after an exclusive licensing agreement with the National Institute of Dental and Craniofacial Research (NIDCR), an arm of the …